ClinicalTrials.gg
CompletedNCT00904111Updated Dec 6, 2013

A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain

A Phase 2 interventional study of Lidoderm® and Placebo Topical Patch in Chronic Low Back Pain, sponsored by Endo Pharmaceuticals. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
137th of 623
215 · median 79
Started
2004
with 14 others
Phase 2
59 of 711
7 open now
Registered
121st of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 137th largest by enrollment of the 623 interventional ones that give a count, is one of 15 that started in 2004, is one of 59 in phase 2, and was the 121st registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

Patients with Chronic Axial Low Back Pain participated in a Phase II clinical trial to assess the efficacy of lidocaine 5% patch compared with placebo.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Had axial LBP with or without radiation present for at least 3 months as defined as:

    • Chronic axial LBP without radiation: pain isolated to the axial low back without radiation into the buttock or below
    • Chronic axial LBP with radiation: pain that radiates to the buttock or below. This patient group could include patients with radicular/neuropathic and non-radicular components with leg pain component \<50%
  • Had daily moderate to severe LBP as the primary source of pain
  • Had a normal neurological examination, including:

    • Motor strength
    • Sensory exam in lower extremities
    • Deep tendon reflexes
  • Had a normal 12-lead (ECG) without any abnormalities in heart rate, rhythm, or conduction
  • Had discontinued use of all analgesic medications (including over-the-counter [OTC] analgesics) prior to randomization (patients were allowed limited use of analgesic medications for indications other than non-study pain).
  • Had a daily average pain intensity rating of 6 or greater (on a 0 to 10 scale) for at least 3 days out of the 5 consecutive days immediately prior to the baseline visit; 0 was defined as "no pain" and 10 was defined as "pain as bad as ever imagined" as measured by Question 5 of the Brief Pain Inventory (BPI) and recorded in a diary

Key Exclusion Criteria:

  • Had spinal stenosis with > 50% leg pain component
  • Had elective surgery scheduled to occur during the 14-week study
  • Had a history of one or more back surgeries within 1 year of study entry
  • Had severe renal insufficiency ( of \<30mL/min)
  • Had moderate or greater hepatic impairment
  • Were taking analgesic medications that could not be discontinued during the study. Patients taking these medications prior to the study were required to discontinue use for the duration of the study. Patients using opioid analgesics at study entry were required to taper off these medications.
  • Were taking long-acting opioids or opioids that could not be discontinued over the first 5 days of the placebo run-in period
  • Had received an epidural /local anesthesia injection within 4 weeks prior to study entry
  • Had received trigger point injections within 2 weeks prior to study entry
  • Had received Botulinum Toxin (Botox) Injections for LBP within 6 months prior to study entry
  • Were using a lidocaine-containing product that could not be discontinued during the study
  • Were using any topical medication applied to the low back region
  • Had previously failed treatment with Lidoderm analgesic patch for LBP
  • Were taking class 1 anti-arrhythmic drugs (e.g. mexiletine, tocainide)
  • Had any other chronic pain condition that, in the opinion of the investigator, would have interfered with patient assessment of LBP relief
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    Lidocaine 5% Patch

    Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)

    Drug: Lidoderm®

  • Placebo comparator
    Placebo Topical Patch

    Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)

    Drug: Placebo Topical Patch

Interventions

  • Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.

    Also known as: Lidocaine 5% Patch

  • DrugPlacebo Topical Patch

    Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.

06

What researchers measure

Primary outcomes

  1. Pain intensity (Question 5 of the BPI)

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day56), V7/EOS (Day 84)

Secondary outcomes

  1. Safety Assessments included AEs, dermal assessments, clinical laboratory results (including urinalysis), vital sign measurements, physical and neurological examinations, plasma lidocaine concentration

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day56), V7/EOS (Day 84)

07

Study locations

18 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Carlsbad, California, United States
  • National City, California, United States
  • Waterbury, Connecticut, United States
  • Washington, District of Columbia, United States
  • Port Orange, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Overland Park, Kansas, United States
  • Pittsfield, Massachusetts, United States
  • Burlington, North Carolina, United States
  • Altoona, Pennsylvania, United States
  • Duncansville, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Cordova, Tennessee, United States
  • San Antonio, Texas, United States
  • Virginia Beach, Virginia, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004 and a primary completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2009
First posted
May 19, 2009
Start
Aug 2004
Primary completionActual
Oct 2005
Last update
Dec 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00904111
First posted
May 19, 2009
Start date
Aug 2004
Primary completion
Oct 2005
Last update
Dec 6, 2013

Study contacts

Study Director
study director · Endo Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion